Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma?

Nature Clinical Practice Oncology volume 2, pages 346–347 (2005)Cite this article

boxed-textKaminski MS et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441–449

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Solal-Celigny P et al. (2004) Follicular lymphoma international prognostic index. Blood 104: 1258–1265

    Article  CAS  Google Scholar 

  2. Brice P et al. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1110–1117

    Article  CAS  Google Scholar 

  3. Cheson BD et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244

    Article  CAS  Google Scholar 

  4. Horning SJ et al. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23: 712–719

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Clinical Medicine at Department of Medicine, New York Weill Cornell University Medical College, and Attending Physician, Lymphoma Service, Memorial Sloan–Kettering Cancer Center, NY, USA

    Carol S Portlock

Authors
  1. Carol S Portlock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol S Portlock.

Ethics declarations

Competing interests

The author has received lecture honoraria from IDEC and Genentech.

Glossary

PROGRESSIVE DISEASE

An increase of at least 25% in the sum of the products of the largest perpendicular diameters from nadir, or a new lesion larger than 2 cm identified by radiography or 1 cm by physical examination, or involvement of bone marrow following complete response or clinical response

CLINICAL RESPONSE

Complete resolution of disease-related symptoms for at least 1 month

COMPLETE RESPONSE (CR)

Disappearance of all disease for at least 1 month or absence of change in minimal residual radiographic abnormalities for at least 6 months

PARTIAL RESPONSE

A reduction of at least 50% in the sum of the products of the largest perpendicular diameters of all measurable lesions for at least 1 month

CHOP

cyclophosphamide, doxorubicin, vincristine, and prednisone

Rights and permissions

Reprints and permissions

About this article

Cite this article

Portlock, C. Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma?. Nat Rev Clin Oncol 2, 346–347 (2005). https://doi.org/10.1038/ncponc0227

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0227

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing